|
INTERNATIONAL JOURNAL OF SCIENTIFIC DEVELOPMENT AND RESEARCH International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2455-2631 | Impact factor: 8.15 | ESTD Year: 2016 open access , Peer-reviewed, and Refereed Journals, Impact factor 8.15 |
Imp Links for Author
Imp Links for Reviewer
Research Area
Subscribe IJSDR
Visitor Counter
Copyright Infringement Claims
Indexing Partner
|
Published Paper Details
|
|
| Paper Title: | POST COVID RHINOORBITAL MUCORMYCOSIS (ROM) - OUR EXPERIENCE IN MANAGEMENT OF DISEASE, ON A SIX MONTH FOLLOW UP OF 60 PATIENTS. |
| Authors Name: | Vijaypradap R , Rajavel MSPS , Maheswaran S , RamaPriyadharshini J , Nithin ragav G |
| Unique Id: | IJSDR2205026 |
| Published In: | Volume 7 Issue 5, May-2022 |
| Abstract: | AIM: Observe the treatment outcome of the patients treated for Post COVID ROM in a tertiary care hospital with 6 month follow up. MATERIALS AND METHODS All patients diagnosed for Post COVID ROM were included in this study. All these patients were subjected to surgical debridement and anti-fungal treatment. The patients were followed up for a period of 6 months and outcome was evaluated based on the postoperative morbidity. RESULTS 60 patients were included in the study. 44 patients had limited disease. 16 patients had extensive disease. All patients underwent surgical debridement and anti-fungal treatment. Repeat imaging was done 3 months to assess the treatment outcome. A complete 6 month follow up was done. CONCLUSION In the early stage of the pandemic, patients who presented very late with extensive disease and were subjected to radical surgical debridement which included orbital exenteration. Later ROM was identified earlier and early surgical intervention was started. Early suspicion and aggressive surgical debridement not only had good outcome, but also reduced the post-operative morbidity. In early disease presentation significant reduction in morbidity and reduced recurrence was observed in patients who have undergone Caldwell Luc surgery to examine the maxillary sinus cavity along with endoscopic debridement for disease clearance in the maxillary sinus floor and anterolateral wall. In delayed presentation and in patients needing Maxillectomy, preservation of mucosa of hard palate had significant reduction in postoperative morbidity without increasing the recurrence rate. |
| Keywords: | Mucormycosis, invasive fungal sinusitis, rhino orbital mucormycosis, Acute fungal sinusitis, Fungal sinusitis, Management of Mucormycosis, Treatment of Mucormycosis, Acute sinusitis, Orbital apex syndrome, Maxillectomy, Orbital exenteration, COVID 19 related Mucormycosis, Mucormycosis epidemic |
| Cite Article: | "POST COVID RHINOORBITAL MUCORMYCOSIS (ROM) - OUR EXPERIENCE IN MANAGEMENT OF DISEASE, ON A SIX MONTH FOLLOW UP OF 60 PATIENTS. ", International Journal of Science & Engineering Development Research (www.ijsdr.org), ISSN:2455-2631, Vol.7, Issue 5, page no.134 - 139, May-2022, Available :http://www.ijsdr.org/papers/IJSDR2205026.pdf |
| Downloads: | 000337072 |
| Publication Details: | Published Paper ID: IJSDR2205026 Registration ID:200327 Published In: Volume 7 Issue 5, May-2022 DOI (Digital Object Identifier): Page No: 134 - 139 Publisher: IJSDR | www.ijsdr.org ISSN Number: 2455-2631 |
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijsdr.org
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | DOAJ : Directory of Open Access Journals |
| DRJI | Index Copernicus International | Scribd | DocStoc |
Track Paper
Important Links
Conference Proposal
ISSN
 |
 |
DOI (A digital object identifier)
  Providing A digital object identifier by DOI How to GET DOI and Hard Copy Related |
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
 |
 |
 |
Social Media
Indexing Partner |
|||
| Copyright © 2024 - All Rights Reserved - IJSDR | |||
Facebook Twitter Instagram LinkedIn